Scinai Immunotherapeutics Reports 167% Revenue Growth in Nine-Month Period
Scinai Immunotherapeutics (SCNI) has reported significant financial improvements for the nine-month period ending September 30, 2025. The company saw a substantial increase in revenue, rising to $2.80 million from $1.05 million during the same period in the previous year. Crucially, the company managed to significantly narrow its net loss, reporting a loss of only $0.39 million compared to a much larger loss of $6.24 million in the prior year's nine-month window. This indicates improved operational efficiency and cost management despite ongoing developmental or market challenges.
